LISA-TRACKER Adalimumab
Product Description
LISA-TRACKER Adalimumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Adalimumab (anti-TNFα) in human serum samples.
- Comprehensive menu in inflammatory diseases and oncology
- Standardised against the 1st International standard (17/236)
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Bendtzen K. Is There a Need for Immunopharmacologic Guidance of Anti–Tumor Necrosis Factor Therapies. ARTHRITIS & RHEUMATISM Vol. 63, No. 4, April 2011, pp 867–870.
- Jaminitski A et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Rheum Dis. 2011 Feb;70(2):284-8.
- Korswagen LA et al. Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Anti-adalimumab Antibodies. ARTHRITIS & RHEUMATISM Vol. 63, No. 4, April 2011, pp 877–883.
- Radstake TRDJ et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
- Ann Rheum Dis 2009;68:1739–1745.
- Sparado A et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010 Jun;49(6):1107-11.
- Wolbink GJ et al. Development of Anti-infliximab Antibodies and Relationship to Clinical Response in Patients With Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM Vol. 54, No. 3, March 2006, pp711–715.
- Product Code: LTA-002-48
- Number of Tests: 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: 0.3 – 20 μg/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER anti-Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Etanercept | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Rituximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Tocilizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |